Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors

5. Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study. Neuroendocrinology 2021; 111: 752–63. doi: 10.1159/000510159 WangW ZhangY PengY JinKZ LiYL LiangY A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study Neuroendocrinology 2021 111 752 63 10.1159/000510159 Open DOISearch in Google Scholar

6. Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022; 23: 493–9. doi: 10.1111/1751-2980.13123 DoganI TastekinD KarabulutS SakarB Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors J Dig Dis 2022 23 493 9 10.1111/1751-2980.13123 Open DOISearch in Google Scholar

7. Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw 2021; 20: 29–36. doi: 10.6004/jnccn.2021.7017 Al-ToubahT PelleE ValoneT HaiderM StrosbergJR Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms J Natl Compr Canc Netw 2021 20 29 36 10.6004/jnccn.2021.7017 Open DOISearch in Google Scholar

8. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268–75. doi: 10.1002/cncr.25425 StrosbergJR FineRL ChoiJ NasirA CoppolaD ChenDT First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 2011 117 268 75 10.1002/cncr.25425 Open DOISearch in Google Scholar

9. Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist 2016; 21: 671–5. doi: 10.1634/theoncologist.2015-0470 RamirezRA BeyerDT ChauhanA BoudreauxJP WangYZ WolteringEA The role of capecitabine/temozolomide in metastatic neuroendocrine tumors Oncologist 2016 21 671 5 10.1634/theoncologist.2015-0470 Open DOISearch in Google Scholar

10. Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag Res 2022; 14: 3507–23. doi: 10.2147/cmar.S372776 ArriviG VerricoM RobertoM BarchiesiG FaggianoA MarchettiP Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis Cancer Manag Res 2022 14 3507 23 10.2147/cmar.S372776 Open DOISearch in Google Scholar

11. Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 759–67. doi: 10.1530/erc-16-0147 CivesM GhayouriM MorseB BrelsfordM BlackM RizzoA Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors Endocr Relat Cancer 2016 23 759 67 10.1530/erc-16-0147 Open DOISearch in Google Scholar

12. Zhang G, Xu Z, Zheng J, Wang M, Ren J, Wei X, et al. Prognostic value of multi b-value DWI in patients with locally advanced rectal cancer. Eur Radiol 2023; 33: 1928–37. doi: 10.1007/s00330-022-09159-7 ZhangG XuZ ZhengJ WangM RenJ WeiX Prognostic value of multi b-value DWI in patients with locally advanced rectal cancer Eur Radiol 2023 33 1928 37 10.1007/s00330-022-09159-7 Open DOISearch in Google Scholar

13. Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, et al. Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters. Biomedicines 2022: 10: 2618. doi: 10.3390/biomedicines10102618 IngenerfM KieslS WinkelmannM AuernhammerCJ RübenthalerJ GraweF Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters Biomedicines 2022 10 2618 10.3390/biomedicines10102618 Open DOISearch in Google Scholar

14. Yuan W, Yu Q, Wang Z, Huang J, Wang J, Long L. Efficacy of diffusion-weighted imaging in neoadjuvant chemotherapy for osteosarcoma: a systematic review and meta-analysis. Acad Radiol 2022; 29: 326–34. doi: 10.1016/j.acra.2020.11.013 YuanW YuQ WangZ HuangJ WangJ LongL Efficacy of diffusion-weighted imaging in neoadjuvant chemotherapy for osteosarcoma: a systematic review and meta-analysis Acad Radiol 2022 29 326 34 10.1016/j.acra.2020.11.013 Open DOISearch in Google Scholar

15. Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, et al. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol 2019; 29: 5160–71. doi: 10.1007/s00330-019-06100-3 LuoY PandeyA GhasabehMA PandeyP VarzanehFN Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization Eur Radiol 2019 29 5160 71 10.1007/s00330-019-06100-3 Open DOISearch in Google Scholar

16. Strosberg JR, Cives M, Brelsford M, Black M, Meeker A, Ghayouri M. Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. J Clin Oncol 2015; 33: 4099. doi: 10.1200/jco.2015.33.15_suppl.4099 StrosbergJR CivesM BrelsfordM BlackM MeekerA GhayouriM Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors J Clin Oncol 2015 33 4099 10.1200/jco.2015.33.15_suppl.4099 Open DOISearch in Google Scholar

17. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296–307. doi: 10.1038/nrc1319 GersonSL MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 2004 4 296 307 10.1038/nrc1319 Open DOISearch in Google Scholar

18. 14. Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffié P, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Annalf Oncol 2001; 12 Suppl 2: S79–82. doi: 10.1093/annonc/12.suppl_2.s79 BaudinE BidartJM BachelotA DucreuxM EliasD RuffiéP Impact of chromogranin A measurement in the work-up of neuroendocrine tumors Annalf Oncol 2001 12 Suppl 2 S79 82 10.1093/annonc/12.suppl_2.s79 Open DOISearch in Google Scholar

19. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011; 96: 3741–9. doi: 10.1210/jc.2011-0666 YaoJC PavelM PhanAT KulkeMH HoosenS St PeterJ Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus J Clin Endocrinol Metab 2011 96 3741 9 10.1210/jc.2011-0666 Open DOISearch in Google Scholar

20. Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, et al. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res 2014; 34: 5661–9. ChouWC ChenJS HungYS HsuJT ChenTC SunCF Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors Anticancer Res 2014 34 5661 9 Search in Google Scholar

21. Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95: 344–50. doi: 10.1159/000333853 ChouWC HungYS HsuJT ChenJS LuCH HwangTL Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients Neuroendocrinology 2012 95 344 50 10.1159/000333853 Open DOISearch in Google Scholar

22. Tsai H-J, Hsiao C-F, Chang JS, Chen L-T, Chao Y-J, Yen C-J, et al. The Prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors – a single-center experience. Front Oncol 2021; 11: 741096. doi: 10.3389/fonc.2021.741096 TsaiH-J HsiaoC-F ChangJS ChenL-T ChaoY-J YenC-J The Prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors – a single-center experience Front Oncol 2021 11 741096 10.3389/fonc.2021.741096 Open DOISearch in Google Scholar

23. de Mestier L, Dromain C, d’Assignies G, Scoazec J-Y, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 2014; 21: R105–R120. doi: 10.1530/erc-13-0365 de MestierL DromainC d’AssigniesG ScoazecJ-Y LassauN LebtahiR Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art Endocr Relat Cancer 2014 21 R105 R120 10.1530/erc-13-0365 Open DOISearch in Google Scholar

24. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132 LencioniR LlovetJM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 2010 30 52 60 10.1055/s-0030-1247132 Open DOISearch in Google Scholar

25. Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol 2018; 20: 1522–8. doi: 10.1007/s12094-018-1881-9 Merino-CasabielX AllerJ ArbizuJ García-FigueirasR GonzálezC GrandeE Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors Clin Transl Oncol 2018 20 1522 8 10.1007/s12094-018-1881-9 Open DOISearch in Google Scholar

26. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in lowto intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 2010; 28: 4002. doi: 10.1200/jco.2010.28.15_suppl.4002 YaoJC PhanAT FoglemanD NgCS JacobsCB DagohoyCD Randomized run-in study of bevacizumab (B) and everolimus (E) in lowto intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker J Clin Oncol 2010 28 4002 10.1200/jco.2010.28.15_suppl.4002 Open DOISearch in Google Scholar

27. Ingenerf MK, Karim H, Fink N, Ilhan H, Ricke J, Treitl KM, et al. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol 2022; 63: 878–88. doi: 10.1177/02841851211024004 IngenerfMK KarimH FinkN IlhanH RickeJ TreitlKM Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study Acta Radiol 2022 63 878 88 10.1177/02841851211024004 Open DOISearch in Google Scholar

28. Min JH, Kang TW, Kim YK, Kim SH, Shin KS, Lee JE, et al. Hepatic neuroendocrine tumour: apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival. Eur Radiol 2018; 28: 2561–71. doi: 10.1007/s00330-017-5248-3 MinJH KangTW KimYK KimSH ShinKS LeeJE Hepatic neuroendocrine tumour: apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival Eur Radiol 2018 28 2561 71 10.1007/s00330-017-5248-3 Open DOISearch in Google Scholar

29. Vandecaveye V, Dresen RC, Pauwels E, Binnebeek SV, Vanslembrouck R, Baete K, et al. Early whole-body diffusion-weighted MRI helps predict long-term outcome following peptide receptor radionuclide therapy for metastatic neuroendocrine tumors. Radiol Imaging Cancer 2022; 4: e210095. doi: 10.1148/rycan.210095 VandecaveyeV DresenRC PauwelsE BinnebeekSV VanslembrouckR BaeteK Early whole-body diffusion-weighted MRI helps predict long-term outcome following peptide receptor radionuclide therapy for metastatic neuroendocrine tumors Radiol Imaging Cancer 2022 4 e210095 10.1148/rycan.210095 Open DOISearch in Google Scholar